Direkt zum Inhalt
Merck

Metabolic acetate therapy for the treatment of traumatic brain injury.

Journal of neurotrauma (2009-10-07)
Peethambaran Arun, Prasanth S Ariyannur, John R Moffett, Guoqiang Xing, Kristen Hamilton, Neil E Grunberg, John A Ives, Aryan M A Namboodiri
ZUSAMMENFASSUNG

Patients suffering from traumatic brain injury (TBI) have decreased markers of energy metabolism, including N-acetylaspartate (NAA) and ATP. In the nervous system, NAA-derived acetate provides acetyl-CoA required for myelin lipid synthesis. Acetate can also be oxidized in mitochondria for the derivation of metabolic energy. In the current study, using the controlled cortical impact model of TBI in rats, we investigated the effects of the hydrophobic acetate precursor, glyceryltriacetate (GTA), as a method of delivering metabolizable acetate to the injured brain. We found that GTA administration significantly increased the levels of both NAA and ATP in the injured hemisphere 4 and 6 days after injury, and also resulted in significantly improved motor performance in rats 3 days after injury.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Glycerin-triacetat, 99%
Sigma-Aldrich
Glycerin-triacetat, 99%, FCC, FG
Sigma-Aldrich
Glycerintriacetat, ≥99%
Sigma-Aldrich
Glycerintriacetat, ≥99.0% (GC)